Preliminary results of interferon- α therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice

Background : C- myc activation is a potent oncogenic event in hepatocarcinogenesis. The aim of this study was to test the preventive effect of interferon- α (IFN- α) on the development of dysplasia and subsequent hepatocellular carcinoma (HCC) in transgenic (Tg) mice overexpressing c- myc in the liv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2001-04, Vol.34 (4), p.562-569
Hauptverfasser: Merle, Philippe, Chevallier, Michèle, Levy, Rafael, Maisonnas, Mireille, Terradillos, Olivier, Si Ahmed, Si Nafa, Trépo, Christian, Buendia, Marie Annick, Vitvitski-Trépo, Ludmila
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 569
container_issue 4
container_start_page 562
container_title Journal of hepatology
container_volume 34
creator Merle, Philippe
Chevallier, Michèle
Levy, Rafael
Maisonnas, Mireille
Terradillos, Olivier
Si Ahmed, Si Nafa
Trépo, Christian
Buendia, Marie Annick
Vitvitski-Trépo, Ludmila
description Background : C- myc activation is a potent oncogenic event in hepatocarcinogenesis. The aim of this study was to test the preventive effect of interferon- α (IFN- α) on the development of dysplasia and subsequent hepatocellular carcinoma (HCC) in transgenic (Tg) mice overexpressing c- myc in the liver. Methods : The WHV/c- myc Tg mice recapitulating woodchuck hepatitis virus-induced hepatocarcinogenesis were treated with IFN- α, starting early in life until sacrifice at pre-neoplastic or neoplastic stages. Transgene expression was assessed by reverse transcription-polymerase chain reaction (RT-PCR), hepatocyte proliferation was assessed by bromodeoxyuridine incorporation and RT-PCR for proliferating cell nuclear antigen, and apoptosis was assessed by in situ nick-end-labeling of DNA. Results : C- myc expression and hepatocyte proliferation were significantly reduced in treated female mice, without modification of apoptosis, correlating with a lower severity of dysplasia in 9/12 treated animals at pre-neoplastic stages. At the neoplastic stage, 2/3 treated females neither exhibited carcinoma nor dysplasia, while all 6/6 untreated mice and 3/3 treated males developed carcinomas. Conclusions : Inhibition of c- myc and hepatocyte proliferation by long-term administration of IFN- α was associated with a decrease, or a delay, of oncogenesis in the mouse Tg HCC model. Whether c- myc and hepatocyte proliferation down-regulation could be relevant parameters of IFN- α efficiency for hepatocarcinogenesis prevention in cirrhotic patients should be established.
doi_str_mv 10.1016/S0168-8278(00)00054-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70914412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827800000544</els_id><sourcerecordid>70914412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-57ca8f391b2d9a09929bb312bc83bc0e6f2024678471fac430d030c9efc26b323</originalsourceid><addsrcrecordid>eNqFkduKFDEQhoMo7rj6CEpAEL1oTbrTh3gjsniCBQX1OqSrK05pdzKbpFf2OXwSX8RnMrMzrJfeJPDzVSr1FWMPpXguhexefC7HUA11PzwV4pkQolWVusU2shOiEp2St9nmBjlh91L6XqBGaHWXnUjZaNW13Yb9-hRxpoW8jVc8YlrnnHhwnHzG6DAGX_E_v3neYrS7Kx48_xnCBNsVfvAt7mymTIlfUlxTRX5aAadDHsBGIB--ocdE6SXfhZRonJGPJXGUSwvucLElydH6VEACvhDgfXbH2Tnhg-N9yr6-ffPl7H11_vHdh7PX5xU0g85V24MdXKPlWE_aCq1rPY6NrEcYmhEEdq4Wter6QfXSWVCNmMr8oNFB3Y1N3ZyyJ4d3dzFcrJiyWSgBzrP1GNZkeqGlUnIPtgcQYhkiojO7SEsxZqQw-22Y622YvWojhLnehlGl7tGxwTouOP2rOuovwOMjYBPY2RUPQOmG061q66FQrw4UFhmXhNEkIPRFNUWEbKZA__nIX3P_qoY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70914412</pqid></control><display><type>article</type><title>Preliminary results of interferon- α therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Merle, Philippe ; Chevallier, Michèle ; Levy, Rafael ; Maisonnas, Mireille ; Terradillos, Olivier ; Si Ahmed, Si Nafa ; Trépo, Christian ; Buendia, Marie Annick ; Vitvitski-Trépo, Ludmila</creator><creatorcontrib>Merle, Philippe ; Chevallier, Michèle ; Levy, Rafael ; Maisonnas, Mireille ; Terradillos, Olivier ; Si Ahmed, Si Nafa ; Trépo, Christian ; Buendia, Marie Annick ; Vitvitski-Trépo, Ludmila</creatorcontrib><description>Background : C- myc activation is a potent oncogenic event in hepatocarcinogenesis. The aim of this study was to test the preventive effect of interferon- α (IFN- α) on the development of dysplasia and subsequent hepatocellular carcinoma (HCC) in transgenic (Tg) mice overexpressing c- myc in the liver. Methods : The WHV/c- myc Tg mice recapitulating woodchuck hepatitis virus-induced hepatocarcinogenesis were treated with IFN- α, starting early in life until sacrifice at pre-neoplastic or neoplastic stages. Transgene expression was assessed by reverse transcription-polymerase chain reaction (RT-PCR), hepatocyte proliferation was assessed by bromodeoxyuridine incorporation and RT-PCR for proliferating cell nuclear antigen, and apoptosis was assessed by in situ nick-end-labeling of DNA. Results : C- myc expression and hepatocyte proliferation were significantly reduced in treated female mice, without modification of apoptosis, correlating with a lower severity of dysplasia in 9/12 treated animals at pre-neoplastic stages. At the neoplastic stage, 2/3 treated females neither exhibited carcinoma nor dysplasia, while all 6/6 untreated mice and 3/3 treated males developed carcinomas. Conclusions : Inhibition of c- myc and hepatocyte proliferation by long-term administration of IFN- α was associated with a decrease, or a delay, of oncogenesis in the mouse Tg HCC model. Whether c- myc and hepatocyte proliferation down-regulation could be relevant parameters of IFN- α efficiency for hepatocarcinogenesis prevention in cirrhotic patients should be established.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/S0168-8278(00)00054-4</identifier><identifier>PMID: 11394656</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Oxford: Elsevier B.V</publisher><subject>Animals ; Apoptosis - drug effects ; Biological and medical sciences ; C- myc ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - prevention &amp; control ; Carcinoma, Hepatocellular - virology ; Cell Division - drug effects ; Dysplasia ; Female ; Hepatitis B - complications ; Hepatitis B Virus, Woodchuck ; Hepatocytes - pathology ; Hepatoma ; Humans ; Immunomodulators ; Interferon ; Interferon-alpha - therapeutic use ; Liver - metabolism ; Liver - pathology ; Liver Neoplasms - pathology ; Liver Neoplasms - prevention &amp; control ; Liver Neoplasms - virology ; Medical sciences ; Mice ; Mice, Transgenic ; Pharmacology. Drug treatments ; Precancerous Conditions - pathology ; Precancerous Conditions - physiopathology ; Precancerous Conditions - prevention &amp; control ; Proliferation ; Proto-Oncogene Proteins c-myc - antagonists &amp; inhibitors ; Proto-Oncogene Proteins c-myc - genetics ; Proto-Oncogene Proteins c-myc - metabolism ; Recombinant Proteins - therapeutic use</subject><ispartof>Journal of hepatology, 2001-04, Vol.34 (4), p.562-569</ispartof><rights>2001 European Association for the Study of the Liver</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-57ca8f391b2d9a09929bb312bc83bc0e6f2024678471fac430d030c9efc26b323</citedby><cites>FETCH-LOGICAL-c389t-57ca8f391b2d9a09929bb312bc83bc0e6f2024678471fac430d030c9efc26b323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0168-8278(00)00054-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=954528$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11394656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Merle, Philippe</creatorcontrib><creatorcontrib>Chevallier, Michèle</creatorcontrib><creatorcontrib>Levy, Rafael</creatorcontrib><creatorcontrib>Maisonnas, Mireille</creatorcontrib><creatorcontrib>Terradillos, Olivier</creatorcontrib><creatorcontrib>Si Ahmed, Si Nafa</creatorcontrib><creatorcontrib>Trépo, Christian</creatorcontrib><creatorcontrib>Buendia, Marie Annick</creatorcontrib><creatorcontrib>Vitvitski-Trépo, Ludmila</creatorcontrib><title>Preliminary results of interferon- α therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Background : C- myc activation is a potent oncogenic event in hepatocarcinogenesis. The aim of this study was to test the preventive effect of interferon- α (IFN- α) on the development of dysplasia and subsequent hepatocellular carcinoma (HCC) in transgenic (Tg) mice overexpressing c- myc in the liver. Methods : The WHV/c- myc Tg mice recapitulating woodchuck hepatitis virus-induced hepatocarcinogenesis were treated with IFN- α, starting early in life until sacrifice at pre-neoplastic or neoplastic stages. Transgene expression was assessed by reverse transcription-polymerase chain reaction (RT-PCR), hepatocyte proliferation was assessed by bromodeoxyuridine incorporation and RT-PCR for proliferating cell nuclear antigen, and apoptosis was assessed by in situ nick-end-labeling of DNA. Results : C- myc expression and hepatocyte proliferation were significantly reduced in treated female mice, without modification of apoptosis, correlating with a lower severity of dysplasia in 9/12 treated animals at pre-neoplastic stages. At the neoplastic stage, 2/3 treated females neither exhibited carcinoma nor dysplasia, while all 6/6 untreated mice and 3/3 treated males developed carcinomas. Conclusions : Inhibition of c- myc and hepatocyte proliferation by long-term administration of IFN- α was associated with a decrease, or a delay, of oncogenesis in the mouse Tg HCC model. Whether c- myc and hepatocyte proliferation down-regulation could be relevant parameters of IFN- α efficiency for hepatocarcinogenesis prevention in cirrhotic patients should be established.</description><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>C- myc</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - prevention &amp; control</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>Cell Division - drug effects</subject><subject>Dysplasia</subject><subject>Female</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B Virus, Woodchuck</subject><subject>Hepatocytes - pathology</subject><subject>Hepatoma</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - prevention &amp; control</subject><subject>Liver Neoplasms - virology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Pharmacology. Drug treatments</subject><subject>Precancerous Conditions - pathology</subject><subject>Precancerous Conditions - physiopathology</subject><subject>Precancerous Conditions - prevention &amp; control</subject><subject>Proliferation</subject><subject>Proto-Oncogene Proteins c-myc - antagonists &amp; inhibitors</subject><subject>Proto-Oncogene Proteins c-myc - genetics</subject><subject>Proto-Oncogene Proteins c-myc - metabolism</subject><subject>Recombinant Proteins - therapeutic use</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkduKFDEQhoMo7rj6CEpAEL1oTbrTh3gjsniCBQX1OqSrK05pdzKbpFf2OXwSX8RnMrMzrJfeJPDzVSr1FWMPpXguhexefC7HUA11PzwV4pkQolWVusU2shOiEp2St9nmBjlh91L6XqBGaHWXnUjZaNW13Yb9-hRxpoW8jVc8YlrnnHhwnHzG6DAGX_E_v3neYrS7Kx48_xnCBNsVfvAt7mymTIlfUlxTRX5aAadDHsBGIB--ocdE6SXfhZRonJGPJXGUSwvucLElydH6VEACvhDgfXbH2Tnhg-N9yr6-ffPl7H11_vHdh7PX5xU0g85V24MdXKPlWE_aCq1rPY6NrEcYmhEEdq4Wter6QfXSWVCNmMr8oNFB3Y1N3ZyyJ4d3dzFcrJiyWSgBzrP1GNZkeqGlUnIPtgcQYhkiojO7SEsxZqQw-22Y622YvWojhLnehlGl7tGxwTouOP2rOuovwOMjYBPY2RUPQOmG061q66FQrw4UFhmXhNEkIPRFNUWEbKZA__nIX3P_qoY</recordid><startdate>20010401</startdate><enddate>20010401</enddate><creator>Merle, Philippe</creator><creator>Chevallier, Michèle</creator><creator>Levy, Rafael</creator><creator>Maisonnas, Mireille</creator><creator>Terradillos, Olivier</creator><creator>Si Ahmed, Si Nafa</creator><creator>Trépo, Christian</creator><creator>Buendia, Marie Annick</creator><creator>Vitvitski-Trépo, Ludmila</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010401</creationdate><title>Preliminary results of interferon- α therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice</title><author>Merle, Philippe ; Chevallier, Michèle ; Levy, Rafael ; Maisonnas, Mireille ; Terradillos, Olivier ; Si Ahmed, Si Nafa ; Trépo, Christian ; Buendia, Marie Annick ; Vitvitski-Trépo, Ludmila</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-57ca8f391b2d9a09929bb312bc83bc0e6f2024678471fac430d030c9efc26b323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>C- myc</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - prevention &amp; control</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>Cell Division - drug effects</topic><topic>Dysplasia</topic><topic>Female</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B Virus, Woodchuck</topic><topic>Hepatocytes - pathology</topic><topic>Hepatoma</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - prevention &amp; control</topic><topic>Liver Neoplasms - virology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Pharmacology. Drug treatments</topic><topic>Precancerous Conditions - pathology</topic><topic>Precancerous Conditions - physiopathology</topic><topic>Precancerous Conditions - prevention &amp; control</topic><topic>Proliferation</topic><topic>Proto-Oncogene Proteins c-myc - antagonists &amp; inhibitors</topic><topic>Proto-Oncogene Proteins c-myc - genetics</topic><topic>Proto-Oncogene Proteins c-myc - metabolism</topic><topic>Recombinant Proteins - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Merle, Philippe</creatorcontrib><creatorcontrib>Chevallier, Michèle</creatorcontrib><creatorcontrib>Levy, Rafael</creatorcontrib><creatorcontrib>Maisonnas, Mireille</creatorcontrib><creatorcontrib>Terradillos, Olivier</creatorcontrib><creatorcontrib>Si Ahmed, Si Nafa</creatorcontrib><creatorcontrib>Trépo, Christian</creatorcontrib><creatorcontrib>Buendia, Marie Annick</creatorcontrib><creatorcontrib>Vitvitski-Trépo, Ludmila</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Merle, Philippe</au><au>Chevallier, Michèle</au><au>Levy, Rafael</au><au>Maisonnas, Mireille</au><au>Terradillos, Olivier</au><au>Si Ahmed, Si Nafa</au><au>Trépo, Christian</au><au>Buendia, Marie Annick</au><au>Vitvitski-Trépo, Ludmila</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary results of interferon- α therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2001-04-01</date><risdate>2001</risdate><volume>34</volume><issue>4</issue><spage>562</spage><epage>569</epage><pages>562-569</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Background : C- myc activation is a potent oncogenic event in hepatocarcinogenesis. The aim of this study was to test the preventive effect of interferon- α (IFN- α) on the development of dysplasia and subsequent hepatocellular carcinoma (HCC) in transgenic (Tg) mice overexpressing c- myc in the liver. Methods : The WHV/c- myc Tg mice recapitulating woodchuck hepatitis virus-induced hepatocarcinogenesis were treated with IFN- α, starting early in life until sacrifice at pre-neoplastic or neoplastic stages. Transgene expression was assessed by reverse transcription-polymerase chain reaction (RT-PCR), hepatocyte proliferation was assessed by bromodeoxyuridine incorporation and RT-PCR for proliferating cell nuclear antigen, and apoptosis was assessed by in situ nick-end-labeling of DNA. Results : C- myc expression and hepatocyte proliferation were significantly reduced in treated female mice, without modification of apoptosis, correlating with a lower severity of dysplasia in 9/12 treated animals at pre-neoplastic stages. At the neoplastic stage, 2/3 treated females neither exhibited carcinoma nor dysplasia, while all 6/6 untreated mice and 3/3 treated males developed carcinomas. Conclusions : Inhibition of c- myc and hepatocyte proliferation by long-term administration of IFN- α was associated with a decrease, or a delay, of oncogenesis in the mouse Tg HCC model. Whether c- myc and hepatocyte proliferation down-regulation could be relevant parameters of IFN- α efficiency for hepatocarcinogenesis prevention in cirrhotic patients should be established.</abstract><cop>Oxford</cop><pub>Elsevier B.V</pub><pmid>11394656</pmid><doi>10.1016/S0168-8278(00)00054-4</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-8278
ispartof Journal of hepatology, 2001-04, Vol.34 (4), p.562-569
issn 0168-8278
1600-0641
language eng
recordid cdi_proquest_miscellaneous_70914412
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Animals
Apoptosis - drug effects
Biological and medical sciences
C- myc
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - prevention & control
Carcinoma, Hepatocellular - virology
Cell Division - drug effects
Dysplasia
Female
Hepatitis B - complications
Hepatitis B Virus, Woodchuck
Hepatocytes - pathology
Hepatoma
Humans
Immunomodulators
Interferon
Interferon-alpha - therapeutic use
Liver - metabolism
Liver - pathology
Liver Neoplasms - pathology
Liver Neoplasms - prevention & control
Liver Neoplasms - virology
Medical sciences
Mice
Mice, Transgenic
Pharmacology. Drug treatments
Precancerous Conditions - pathology
Precancerous Conditions - physiopathology
Precancerous Conditions - prevention & control
Proliferation
Proto-Oncogene Proteins c-myc - antagonists & inhibitors
Proto-Oncogene Proteins c-myc - genetics
Proto-Oncogene Proteins c-myc - metabolism
Recombinant Proteins - therapeutic use
title Preliminary results of interferon- α therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T23%3A42%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20results%20of%20interferon-%20%CE%B1%20therapy%20on%20woodchuck%20hepatitis%20virus-induced%20hepatocarcinogenesis:%20possible%20benefit%20in%20female%20transgenic%20mice&rft.jtitle=Journal%20of%20hepatology&rft.au=Merle,%20Philippe&rft.date=2001-04-01&rft.volume=34&rft.issue=4&rft.spage=562&rft.epage=569&rft.pages=562-569&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/S0168-8278(00)00054-4&rft_dat=%3Cproquest_cross%3E70914412%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70914412&rft_id=info:pmid/11394656&rft_els_id=S0168827800000544&rfr_iscdi=true